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Abstract
Acquired carbapenemases are emerging resistance determinants in Gram-negative pathogens, including Enterobacteriaceae, Pseudomonas
aeruginosa and other Gram-negative non-fermenters. A consistent number of acquired carbapenemases have been identiﬁed during the
past few years, belonging to either molecular class B (metallo-b-lactamases) or molecular classes A and D (serine carbapenemases), and
genes encoding these enzymes are associated with mobile genetic elements that allow their rapid dissemination in the clinical setting.
Therefore, detection and surveillance of carbapenemase-producing organisms have become matters of major importance for the selec-
tion of appropriate therapeutic schemes and the implementation of infection control measures. As carbapenemase production cannot
be simply inferred from the resistance proﬁle, criteria must be established for which isolates should be suspected and screened for
carbapenemase production, and for which tests (phenotypic and/or genotypic) should be adopted for conﬁrmation of the resistance
mechanism. Moreover, strategies should be devised for surveillance of carbapenemase producers in order to enable the implementation
of effective surveillance programmes. The above issues are addressed in this article, as a follow-up to an expert meeting on acquired
carbapenemases that was recently organized by the ESCMID Study Group for Antibiotic Resistance Surveillance.
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Introduction
The vast majority of acquired carbapenemases belong to
three of the four known classes of b-lactamases, namely
Ambler class B (metallo-b-lactamases (MBLs)), Ambler
class A, and Ambler class D (oxacillinases (OXAs)). The
bacterial host ranges of these three distinct classes of
enzyme, which confer clinically signiﬁcant resistance to
carbapenems, varies (Table 1). MBLs, mainly of the VIM and
IMP types, have spread mostly in Pseudomonas aeruginosa,
and, at least in some regions, in Acinetobacter baumannii and
Enterobacteriaceae, especially Klebsiella pneumoniae [1,2]. Also,
the latter species has been the main producer of the KPC-
type class A carbapenemases so far [1,3], although other
species in which these enzymes have been identiﬁed include
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Klebsiella oxytoca, Salmonella enterica, Escherichia coli, Enterob-
acter spp., and Pseudomonas spp. [1,4–7]. In addition, rarer
class A enzymes of the GES type, which are typical
extended-spectrum b-lactamases (ESBLs) with the activity
spectrum expanded towards carbapenems, have been identi-
ﬁed in P. aeruginosa, K. pneumoniae and E. coli [8,9]. Acquired
OXA-type carbapenem-hydrolyzing class D b-lactamases
(CHDLs) of the OXA-23, OXA-24/OXA-40 and OXA-58
subfamilies are common among A. baumannii isolates [1,10],
and OXA-48 has been detected in K. pneumoniae and E. coli
isolates [11,12].
The potential for further evolution of this scenario should
not be ignored. Rapid changes in the carbapenemase host
range may occur, because these genes are associated with
mobile genetic elements, and the emergence of novel
enzyme types and variants can be expected in the future.
Laboratory Detection of Carbapenemase-
producing Organisms
Detection of carbapenemase-producing (CP) organisms in
the clinical microbiology laboratory is a matter of major
importance for the choice of appropriate therapeutic
schemes and the implementation of infection control
measures. Detection of carbapenemase producers, how-
ever, poses a number of difﬁculties, as it cannot be based
simply on the resistance proﬁle, and as the relevant meth-
odology based on speciﬁc tests has not yet been well
standardized.
Which isolates should be tested for carbapenemase produc-
tion?
The production of a given carbapenemase may confer a par-
ticular b-lactam resistance phenotype, depending on the bac-
terial species, the expression level, the enzyme type or
variant, and the presence of additional resistance mechanisms
such as permeability reduction and/or efﬂux and/or activity
of other b-lactamases [1,13]. A signiﬁcantly elevated MIC (or
a decreased inhibition zone with disk diffusion testing) of a
carbapenem should make a clinical isolate eligible for further
testing for carbapenemase production by means of speciﬁc
methods (see below). However, carbapenem MICs for carba-
penemase producers may vary within a broad range of val-
ues, and even lay within the susceptibility range, as deﬁned
by either the current CLSI or the EUCAST clinical break-
points (Table 2). Indeed, such low levels of resistance to car-
bapenems have often been observed in Enterobacteriaceae
producing carbapenemases of different types [14–16], Acineto-
bacter isolates producing MBLs [17] and CHDLs, [18] and,
although rarely, among MBL-producing P. aeruginosa isolates
[19]. In order to propose selection criteria for clinical iso-
lates undergoing speciﬁc testing for carbapenemase detection
(screening), one should take into account the carbapenem
MIC ranges reported so far for CP isolates (Table 3), the
distribution of carbapenem MICs in wild-type microorgan-
isms (Table 2; see also MIC distributions of wild-type micro-
organisms at http://www.eucast.org), and certain
characteristics of resistance phenotypes conferred by various
mechanisms.
In a previous discussion paper on MBLs, it was proposed
that MBL production in P. aeruginosa, other Pseudomonas spp.
TABLE 1. Species distribution of clinically relevant acquired
carbapenemases
Organism
MBLs
(class B)
Class A
KPC (GES)
OXA
(class D)
Pseudomonads
Pseudomonas aeruginosa ++ + +
Pseudomonas putida + +
Acinetobacter baumannii +a ++
Acinetobacter spp. + +
Enterobacteria
Klebsiella pneumoniae +a ++ +
Escherichia coli + + +
Proteus mirabilis + +
Providencia spp. +
Klebsiella oxytoca + +
Serratia marcescens +a +
Enterobacter spp. +a +
Citrobacter freundii + +
Morganella morganii +
Salmonella enterica +
Raoultella spp. +
MBL, metallo-b-lactamase.
++, prevalent species–enzyme type combinations; +, occasionally reported spe-
cies–enzyme type combinations.
aEndemic in certain regions.
Crosses in bold denote higher prevalence in the respective species.
TABLE 2. CLSI and EUCAST carbapenem clinical break-
points and epidemiological cut-off values (ECOFFs) (MIC
values, mg/L)
Organisms
CLSI EUCAST
S (£) R (‡) S (£) R (>) ECOFF (>)
Enterobacteriaceae
Imipenem 4 8 2 8 1–4
Meropenem 4 8 2 8 0.125–0.25
Ertapenem 2 4 0.5 1 0.064
Doripenem ND ND 1 4 0.064
Pseudomonas aeruginosa
Imipenem 4 16 4 8 4
Meropenem 4 16 2 8 2
Doripenem ND ND 1 4 1
Acinetobacter spp.
Imipenem 4 16 2 8 1
Meropenem 4 16 2 8 2
Doripenem ND ND 1 4 1
ND, not deﬁned.
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and Acinetobacter spp. should be further investigated in iso-
lates that are non-susceptible to carbapenems (imipenem
and/or meropenem) and resistant either to ticarcillin, ticarcil-
lin–clavulanate or ceftazidime [20]. In general, this proposal
seems still to be appropriate for MBLs and could also be
extended to other carbapenemases, even though there are
some differences in the breakpoints recommended by differ-
ent institutions. For example, the EUCAST and CLSI guide-
lines deﬁne as imipenem-non-susceptible those strains of
A. baumannii with MICs of ‡4 mg/L or ‡8 mg/L, respectively,
and as meropenem-non-susceptible those strains of A. bau-
mannii and P. aeruginosa with MICs of ‡4 mg/L or ‡8 mg/L,
respectively (Table 2).
In the case of Enterobacteriaceae, it is now suggested that
carbapenemase-detecting phenotypic tests should be per-
formed in isolates exhibiting even a small reduction of sus-
ceptibility to carbapenems, including ertapenem, which was
recently found to be a sensitive marker of KPC production
[21]. The CLSI recommends MIC values of ‡2 mg/L for er-
tapenem, imipenem or meropenem, and resistance to at least
one cephalosporin of subclass lll (ceftotaxime, ceftriaxone or
ceftazidime) as indicators of possible carbapenemase produc-
tion in Enterobacteriaceae [22]. However, the CLSI experi-
ence is mostly based on KPC producers. Even less stringent
criteria have been proposed, which recommend ertapenem
or meropenem MICs of ‡0.5 mg/L or imipenem MICs of
‡1 mg/L as cut-off values for suspicion of carbapenemase
production [23]. Similarly, for the disk diffusion methodology,
the CLSI proposes zone diameter cut-off values of £21 mm
for ertapenem or meropenem [22], whereas other authors
have recently recommended £21 mm for ertapenem,
£20 mm for imipenem or even £27 mm for meropenem
[23]. An adequately high sensitivity is expected with applica-
tion of the less stringent criteria, although a number of non-
speciﬁc, false-positive results may be obtained, especially with
ertapenem and with isolates producing either higher amounts
of AmpC-type cephalosporinases or CTX-M ESBLs and with
porin alterations [23,24]. Nevertheless, further adjustment of
the cut-offs may be necessary following the growing experi-
ence with CP clinical isolates.
A concomitant examination of additional phenotypic traits
could assist in detection of CP organisms. Irrespective of the
actual levels of resistance to carbapenems, acquisition of a
carbapenemase affects the susceptibility to a wide variety of
b-lactam antibiotics. In Table 4, the expected ‘baseline’ resis-
tance proﬁles conferred by carbapenemase production in
TABLE 3. Ranges of carbapenem
MICs observed in clinical isolates
producing acquired carbapenemasesOrganism/enzyme type
MICs (mg/L)
Imipenem Meropenem Ertapenem
Pseudomonas aeruginosa/MBL 2 to >64 2 to >64 –
P. aeruginosa/KPC >64 >32 –
Acinetobacter baumannii/MBL 2 to >64 2 to >64 –
A. baumannii/OXA 1 to >64 1 to >64 –
Enterobacteriaceae AmpC())/MBL 0.5 to >64 0.25 to >64 0.5–4(?) Not
enough dataa
Enterobacteriaceae AmpC(+)/MBL 1 to >32 1 to >32 Not enough
dataa
Enterobacteriaceae AmpC())/KPC 0.5 to >64 1 to >32 0.5 to >64
Enterobacteriaceae AmpC(+)/KPC 8 to >64 4–64 8 to >64
Enterobacteriaceae AmpC())/OXA (OXA-48) 1 to >64 0.5–64 4 to >64
MBL, metallo-b-lactamase.
aMost of the papers do not include ertapenem MIC values.
(?)Upper limit uncertain.
TABLE 4. Expected phenotypes of carbapenemase producers for selected b-lactams
Organism Enzyme AMP TIC TZP CAZ ATM IMP ETP
Pseudomonas aeruginosa MBL – R R R S R –
KPC – R R R R R –
Acinetobacter baumannii MBL R R R R S I/R –
OXA R R I S S I/R –
Enterobacteriaceae AmpC()) MBL R R S/I R S S/I/R I/R
Enterobacteriaceae AmpC(+) MBL – R S/I R S S/I/R I/R
Enterobacteriaceae AmpC()) KPC/GES R R R I/R R S/I/R I/R
Enterobacteriaceae AmpC(+) KPC/GES – R R R R I/R I/R
Enterobacteriaceae AmpC()) OXA-48 R R R I/S S S/I S/I
MBL, metallo-b-lactamase; AMP, ampicillin; TIC, ticarcillin; TZP, piperacillin/tazobactam; CAZ, ceftazidime; ATM, aztreonam; IMP, imipenem; ETP, ertapenem.
Phenotypes may vary for many organism–compound combinations, depending on enzyme variants, expression level or additional mechanisms.
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Gram-negative bacteria are indicated. A CP isolate is
expected to exhibit resistance at least to penicillins and nar-
row-spectrum cephalosporins. Also, production of either a
KPC-like or GES-like class A carbapenemase or of an MBL
commonly mediates resistance to expanded-spectrum cepha-
losporins, such as ceftazidime, cefotaxime and ceftriaxone
[1]. Nevertheless, activity of the latter drugs against CHDL
producers is not necessarily compromised [10], and activity
against organisms with other, rare class A carbapenemases
(e.g. SME, IMI and NMC-A) is usually not compromised at
all [1].
Finally, it should be underscored that determination of
carbapenem MICs in organisms producing either a KPC or
an MBL can be problematic. There have been studies report-
ing relatively low reproducibility for most of the conventional
methods used, as well as discrepant results among the meth-
ods [25–27]. At least in part, these problems could be due
to a strong inoculum effect and to the often low carbapenem
MICs mediated by these b-lactamases in Enterobacteriaceae.
Therefore, special care should be applied in preparing bacte-
rial inocula, mostly when automated systems are used
[25,27]. Under-inoculation has been suspected as the main
cause of false-negative results in the detection of KPC
producers [26,27]. Inconsistencies have also been reported
for the gradient diffusion methodologies, such as the Etest
[27–29]. Moreover, the latter methods are not considered
to be appropriate for the KPC-producing organisms, owing
to their heterogeneous growth, which makes the inter-
pretation very difﬁcult [27]. The broth microdilution and
disk diffusion methods are considered to be more reliable
for the detection of all types of carbapenemase-mediated
resistance.
Phenotypic tests for detection of carbapenemase
production
A number of simple phenotypic tests, most of them in the
disk diffusion format, have been described and evaluated as
methodologies for the speciﬁc detection of CP organisms.
The clover leaf method (or modiﬁed Hodge test (MHT))
has been extensively used as a general phenotypic method
for the detection of carbapenemase activity [22,30], and it
has been the only method of carbapenemase detection so
far recommended by the CLSI [22]. The test is based on the
inactivation of a carbapenem by either whole cells or cell
extracts of the CP organisms, which enables a carbapenem-
susceptible indicator strain to extend growth towards a
carbapenem disk, along the streak of inoculum of the test
strain or extract thereof. The assay is, overall, sensitive for
the detection of a carbapenemase-mediated mechanism of
resistance to carbapenems but does not provide information
regarding the type of carbapenemase involved. Moreover,
there have been reports of false-positive results, mostly gen-
erated by CTX-M-producing strains with reduced outer
membrane permeability, and some investigators have raised
the problem of difﬁculties in the interpretation of the clover
leaf test for weak carbapenemase producers, particularly for
MBLs in Enterobacteriaceae [23]. In the case of MBL produc-
ers, it has been suggested that addition of zinc sulphate may
improve the MHT performance [31]. In settings where KPC-
producing K. pneumoniae isolates are endemic, the accurate
determination of levels of susceptibility to ertapenem and
the MHT have been proposed as methods that are sensitive
enough for detection of those isolates, although with insufﬁ-
cient speciﬁcity [21].
Several inhibitor-based tests have been developed for the
speciﬁc detection of MBL producers. These are based on the
synergy between MBL inhibitors—such as EDTA [30,32],
EDTA plus 1,10-phenanthroline [33], thiol compounds (2-
mercaptopropionic acid or sodium mercaptoacetic acid)
[31,34] and dipicolinic acid [35]—and a carbapenem (imipe-
nem and/or meropenem) and/or an oxyimino-cephalosporin
(ceftazidime) as indicator b-lactam compounds. These tests
take advantage of the metalloenzyme dependence on zinc
ions, and use the chelating agents to inhibit b-lactam hydroly-
sis. Various formats (disk diffusion or broth dilution) of
EDTA-based synergy tests have been the most commonly
used and evaluated [30–33]. The double-disk synergy test
(DDST) and the combined disk test, using different amounts
of EDTA and, in the case of DDST, different distances
between the disks, exhibit high sensitivity even with isolates
with low carbapenem resistance levels. It has been suggested
that zinc supplementation of the culture medium may
increase the sensitivity of the method [36], but this modiﬁca-
tion has not been thoroughly evaluated. The Etest MBL strip
is also based on synergy between EDTA and imipenem, and
has been credited with good sensitivity and speciﬁcity for
detection of MBL-producing P. aeruginosa [37], although it
has been repeatedly pointed out that its speciﬁcity might be
impaired by, among other factors, the possible intrinsic activ-
ity of EDTA [28,38,39].
There have been studies reporting failures of EDTA-syn-
ergy tests to detect MBL production among A. baumannii iso-
lates [17,40,41], and a better performance of thiol-based
tests has been indicated [31]. Also, false-positive results in
A. baumannii due to the presence of CHDLs have been
reported [42]. The Etest MBL has proved inappropriate for
detection of MBL-producing Enterobacteriaceae with low imip-
enem MICs (£4 mg/L), but new Etest strips have recently
been developed for the detection of MBLs in Enterobacteria-
ceae, with promising preliminary results [43].
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Despite the good performance of inhibitor tests in the
detection of MBLs in general, it should be remembered that
MBL inhibitors act non-speciﬁcally and affect other structures
and processes (e.g. outer membrane permeabilization in
P. aeruginosa) [38]. The risk of obtaining false or ambiguous
results is certainly higher than in the case of ESBL detection,
with the use of mechanism-based b-lactam inhibitors. There-
fore, the results should be interpreted cautiously, and it is
strongly recommended to have them conﬁrmed with refer-
ence methodology (spectrophotometric assays—see below).
All inhibitor-based synergy tests should include a control for
the intrinsic activity of the inhibitor.
Speciﬁc phenotypic assays for the identiﬁcation of KPC-
producing strains (and of those producing other class A
carbapenemases) are based on the inhibitory effect of
boronic acids, usually 3-aminophenylboronic acid (APB),
although the mechanism of inhibition is not known. Several
versions of such tests have been recently developed,
differing in performance [23,44,45]. Although, in one of
these studies, the DDST approach was found to work well
[23], the combined disk test variant has been applied
more often and, so far, evaluated as being better. Of
several indicator b-lactams tested, either meropenem [45]
or imipenem [23] were pointed out as the preferable
compounds. Also different cut-off values of zone diameter
differences between disks with a carbapenem plus APB
and the carbapenem alone were proposed as being indica-
tive of production of KPC (or another class A carba-
penemase) (‡4 to ‡7 mm). With the use of meropenem
disks, with or without 400 lg of APB, the speciﬁcity in
diagnosing KPC-producing K. pneumoniae isolates and differ-
entiating them from plasmidic AmpC-producing K. pneumo-
niae and E. coli proved excellent [45]. Apart from the disk
diffusion approaches, a method has been developed in
which MICs of carbapenems are evaluated both in the
absence and in the presence of APB (0.3 g/L) by agar dilu-
tion [23]. A three-fold or greater reduction of carbapenem
MIC in the presence of APB has been proposed as the
cut-off value for positive isolates. In general, it seems that
the boronic acid-based methods exhibit high sensitivity
in the detection of KPC producers, which makes these
methods very promising. However, their speciﬁcity needs
further evaluation. Preliminary—and often still unpub-
lished—observations indicate a tendency for false-positive
results to be generated, mostly as a result of organisms
with reduced susceptibility to carbapenems because of
high-level expression of AmpC-type cephalosporinases and
porin alterations [23]. This is not surprising when one
considers the signiﬁcant inhibition of AmpCs by boronic
acids [46]. It is noteworthy that the APB-based assays
failed to detect the KPC-producing Klebsiella isolates in the
case of co-production of VIM enzyme [47].
The enzymatic properties of CHDLs have prevented the
development of speciﬁc phenotypic tests for their detection.
Even the utility of the MHT for CHDL producers has not
been systematically studied. Thus, the deﬁnitive identiﬁcation
of such organisms requires molecular techniques, e.g. PCR
assays speciﬁc for the respective genes.
A group of experts from EUCAST and the ESCMID Study
Group for Antibiotic Resistance Suveillance (EARSS) has rec-
ommended the following procedures for the detection of
class A and B enzymes in Enterobacteriaceae. For class A
enzymes (KPC or other enzymes), production is suspected
when a difference of ‡4 mm in the zone diameter is
observed between meropenem (10 lg) and meropenem plus
boronic acid (600 lg). As boronic acid can also inhibit
class C enzymes, comparison between the zone diameters of
meropenem and meropenem plus cloxacillin (750 lg) disks
suggests the presence of a strain hyperproducing the chro-
mosomal AmpC or producing a plasmid-encoded AmpC
when the latter diameter is increased by ‡5 mm. The detec-
tion of class B enzymes is based on a disk combination test
using meropenem and meropenem plus EDTA (0.25 M). The
test is considered to be positive when there is an increase
in the zone diameter of ‡5 mm. This approach is, overall,
similar to that proposed by different investigators who
have recommended the use of different disks containing a
carbapenem disk with EDTA and boronic acid but with dif-
ferent concentrations [44,45], with the exception that these
protocols cannot differentiate class A carbapenemases from
the combination of class C b-lactamases or ESBLs and porin
loss. However, when meropenem disks with 400 lg of boro-
nate were used, it was possible to accurately discriminate
KPC producers from KPC-negative K. pneumoniae showing
reduced carbapenem susceptibility due to permeability
defects, using suitable breakpoints [45]. The authors claim
that, with these disk tests, carbapenemases can easily be
detected from the ﬁrst isolation day with no need for esti-
mation of Etest carbapenem MICs and of carbapenemase
production on the next day using the clover leaf test.
Carbapenemase detection by spectrophotometric assays
Spectrophotometric measurement of carbapenem hydrolysis
is considered to be the reference standard method for
detection of carbapenemase production in a suspected CP
organism. Hydrolysis of carbapenems in the presence or
absence of inhibitors (i.e. EDTA for MBLs, tazobactam or
clavulanic acid for KPCs, NaCl for most CHDLs), performed
with crude cell extracts or partially puriﬁed enzymes, could
provide additional information concerning the enzyme type.
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These laborious and technically demanding assays should be
performed in reference laboratories.
Detection of carbapenemase genes by molecular methods
Molecular methods such as simplex and multiplex PCRs,
real-time PCR, DNA hybridization and sequencing have been
commonly used for the identiﬁcation of carbapenemase
genes in research laboratories and reference centres. Nowa-
days, some of these methods, mostly PCR, are routinely per-
formed in some clinical laboratories in order to circumvent
the problems of the phenotypic detection of CP organisms.
Apart from the ‘in-house’ assays, there are also commercially
available kits based on PCR and hybridization, examples
being Hyplex MBL ID and Hyplex CarbOxa ID (BAG Health
Care, Lich, Germany) for the detection of blaVIM(1–13) and
blaIMP(1–22) genes and of blaOXA carbapenemase genes,
respectively. This methodology allows detection of the
carbapenemase-encoding genes directly from clinical samples
[48,49].
Commercial kits of this type seem to be promising, and
their thorough evaluation in multicentre studies must be
considered.
Surveillance of Carbapenemase-producing
Microorganisms
Importance of surveillance and the current situation
Surveillance of the occurrence and spread of resistant
organisms is a crucial step for containment of antimicrobial
resistance [50]. ESBL-producing organisms have drawn the
attention of national and international surveillance systems,
probably because ESBLs have become a public health prob-
lem in most countries, and there are well-standardized pro-
tocols and tools for phenotypic detection of these enzymes
[22]. Unlike this situation, acquired carbapenemases have
been reported in fewer geographical areas, and endemicity
seems to be still limited to certain countries, such as Greece,
Italy, Israel, Japan, Brazil and the USA [1–3,51]. Moreover,
difﬁculties in the phenotypic detection of these isolates and
the lack of appropriate standardized methods (see above)
complicate surveillance studies and could lead to an under-
estimation of the actual epidemiological impact of CP organ-
isms. The dearth of surveillance data on bacteria producing
acquired carbapenemases could also reﬂect the fact that
different resistance mechanisms can affect carbapenems,
whereas the presence of multiple mechanisms is often
required for an isolate to be resistant to this antimicrobial
class [52]. In fact, expression of acquired carbapenemases
alone, especially in Enterobacteriaceae, often results in carba-
penem MIC values that remain lower than the current
breakpoints (see above).
For these reasons, in surveillance data, only carbapenem
resistance is normally recorded, but not the resistance
mechanisms involved. This can be further complicated by the
fact that the antimicrobial susceptibility testing committees,
the CLSI and EUCAST, have deﬁned different clinical break-
points for carbapenems (Table 2). Although EUCAST break-
points are, overall, lower than those deﬁned by the CLSI,
they cannot be used accurately to deﬁne or to discriminate
which isolates are putative carbapenemase producers, as the
carbapenem MIC values for these isolates may remain lower
than the breakpoints (see above). EUCAST has also estab-
lished the epidemiological cut-off values (ECOFFs) that dis-
criminate wild-type isolates, lacking a resistance mechanism,
from those possessing any resistance mechanisms affecting
the considered antibiotic (Table 2). Although the use of EC-
OFFs could clearly favour carbapenemase surveillance sys-
tems, some investigators have raised the possibility of the
isolation of Enterobacteriaceae for which carbapenem MICs
are below ECOFFs [16,53]. If these isolates become preva-
lent, and further studies demonstrate their clinical relevance,
additional drawbacks should be resolved in surveillance stud-
ies and also in the process of setting breakpoints. The use of
the most affected carbapenem as an indicator of the pres-
ence of a resistance mechanism, or several carbapenems at
the same time, might help to partially solve this problem.
Finally, it should also be noted that carbapenem breakpoints
are currently under discussion both at the CLSI and EU-
CAST, and some revisions are expected in the near future.
Another approach to the surveillance of acquired carba-
penemases is to establish criteria based on phenotypes in
order to indicate the potential presence of these enzymes.
This approach should be combined with conﬁrmatory tests
that resolve suspected isolates. This was partially addressed
in a previous document, where phenotypes endowed with
the production of a carbapenemase were considered and a
low-stringency consensus was established [20]. This consen-
sus still retains its validity (see above). In the particular case
of MBLs, resistance to ceftazidime and susceptibility to azt-
reonam might also indicate the presence of these enzymes.
Nevertheless, this phenotypic rule should be used with
caution, as it is not infrequent for MBL-producing isolates,
particularly Enterobacteriaceae, to also have other resistance
mechanisms affecting monobactams, such as ESBLs, plasmid-
mediated AmpCs, or hyperproduction of chromosomal
b-lactamases [16,54,55].
As one of the main objectives of antimicrobial surveillance
systems is to detect and warn of the emergence and spread
of new resistance mechanisms, carbapenemase surveillance
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systems are urgently needed. Early warning systems at a
regional or national level should ensure the detection of the
emergence of CP organisms in areas where such isolates
have not previously been reported. Moreover, continuous
surveillance efforts in countries with high prevalence should
provide data for the monitoring of both resistance trends
and the impact of control strategies. A common database at
the international or regional level is also desirable. The
EARSS system is an example of a successful effort funded by
public health authorities (http://www.rivm.nl/earss/). In addi-
tion, private surveillance systems, generally funded by phar-
maceutical companies, such as the SENTRY, TEST, SMART
or MYSTIC programmes, should also contribute to the
knowledge of carbapenemase-producing organisms.
The importance of surveillance is underscored by the fact
that the appearance of acquired carbapenemases in different
countries has been associated with imported cases, mainly
due to the transfer of patients from geographical areas
where this problem is widely established. As an example,
KPC-type enzymes in K. pneumoniae isolates were ﬁrst
reported in 2001 in North Carolina and, until 2005, the geo-
graphical distribution of these enzymes in K. pneumoniae was
limited to the eastern USA [3]. In the New York area, KPC-
producing strains became frequently encountered nosocomial
pathogens, but were also detected in long-term-care facilities
[4,56]. The emergence of KPC-producing Enterobacteriaceae
in France was associated with travel to New York City [3],
and international or intercontinental spread of KPC-produc-
ing K. pneumoniae isolates belonging to sequence type
(ST) 258 has been reported from Israel [57] and several
European countries, including Greece [58], the UK [59],
Poland [60], Norway and Sweden [61], and Italy [62]. The
emergence of these enzymes in the UK, Norway and Swe-
den was, in part, linked with previous patient hospitalization
in Israel and Greece [59,61]. This was also the case for out-
breaks due to VIM-1-producing Enterobacteriaceae reported
in French hospitals [54,63].
Case deﬁnition, denominators and epidemiological data
Like other surveillance systems, a system for surveying bac-
teria producing acquired carbapenemases should be able to
record denominators, and to accurately establish incidence,
prevalence and trends. Moreover, in light of the lessons
learned with ESBLs, speciﬁc efforts should be made to clearly
identify colonized and infected patients. Unlike the situation
with ESBLs, animals in the food chain have not yet been
associated with this problem, probably because the use of
carbapenems in animals is prohibited. Nevertheless, contami-
nation of aquatic settings with relevant carbapenemase pro-
ducers [64,65] can favour and accelerate their spread to
other settings; thus, surveillance studies targeting food-chain
animals and environmental sources might contribute to trac-
ing the potential pathways of carbapenemase dissemination
and the possible involvement of non-human compartments.
Table 5 contains different target objectives for the surveil-
lance of acquired carbapenemases. Relevant information
should be recorded in each case, with a clear deﬁnition of
cases and denominators. At patient or carrier levels, this
information should include, among data, demographics and
risk factors and/or clinical features, including previous hospi-
talizations, travel to countries with a high incidence of CP
organisms, relationship with long-term-care facilities, previ-
ous underlying disease, and antibiotic exposure.
Generally speaking, it is recognized that a case deﬁnition
is needed for an acquired carbapenemase surveillance pro-
gramme. This should be implemented at different levels,
including patients, isolates and clones. Even different enzymes
and the corresponding genes should be considered. Despite
the lack of high levels of expression of carbapenemases,
case deﬁnitions are easier for Enterobacteriaceae than for
P. aeruginosa and Acinetobacter spp., which can have different
resistance mechanisms affecting carbapenems [52].
Surveillance of high-risk clones of carbapenemase-producing
organisms
Surveillance systems should also be designed to investigate
the population structure of CP organisms and to identify
the so-called high-risk clones, as occurs with ESBLs [66].
Different typing systems can be used to broaden this epide-
miological information.
Typing should be performed not only during outbreaks
but also with sporadic isolates for comparison with ‘epi-
demic’ strains. In general, pulsed-ﬁeld gel electrophoresis
should not be used as the only reference typing system,
especially in geographical areas with long-term persistence of
TABLE 5. Target objectives of acquired carbapenemase sur-
veillance systems
Target objectives Speciﬁc indicators
Carbapenem resistance Imipenem, meropenem, ertapenem, doripenem
Acquired
carbapenemase-producing
isolates
Pseudomonas aeruginosa
Acinetobacter spp.
Enterobacteriaceae (Escherichia coli, Klebsiella
pneumoniae, Enterobacter spp., Proteus mirabilis,
others)
Types of enzyme Class A (KPCs)
Class B (mainly VIM and IMP)
Class D (OXA variants affecting carbapenems)
Patients/individuals Clinical (infections) and colonization (carriers)
isolates
Hospitalized and non-hospitalized patients
Healthy population
Non-hospital compartments Food-chain animals
Environment
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acquired CP isolates. In this case, it is more useful to per-
form multilocus sequence typing to track clones and clonal
complexes and to exchange information among different geo-
graphical areas, particularly to identify the emergence of
highly epidemic clones in areas with low prevalence. This
approach can also be useful for the identiﬁcation of highly
epidemic clones associated with speciﬁc carbapenemases,
such as P. aeruginosa ST235, which mainly produces the VIM-
1 enzyme but that was previously recognized to produce the
PER-1 ESBL [67–69]. K. pneumoniae ST258 has been identi-
ﬁed as a plasmid-mediated KPC carbapenemase producer in
several countries [3,54,57–59,70]. The implementation of
commercial easy-to-perform typing systems could also be
useful, as recently shown with ESBL-producing isolates [71].
It is recommended that reference centres in different coun-
tries centralize data.
In these STs and clonal complexes, virulence and pathoge-
nicity should also be investigated. It is recommended that
these studies should be restricted to reference laboratories,
particularly in countries with low-level incidence.
Surveillance of carbapenemase genes and of cognate
genetic platforms and plasmids
In a second step, speciﬁc surveillance studies should be
designed to address the epidemiology of carbapenemase
genes and the cognate genetic platforms participating in their
expression, maintenance and mobilization. This should be
organized in different geographical areas, at both national
and international levels. Moreover, a catalogue of plasmids
carrying carbapenemase genes should be established to con-
tribute to the understanding of the spread of these enzymes.
In surveillance systems for acquired carbapenemases,
co-resistances must also be monitored, as well as the
association of carbapenemase genes with those affecting non-
b-lactam antibiotics. Most of them have been demonstrated
to be transferable, including those recently described as
affecting ﬂuoroquinolones (e.g. qnr, aac(6¢)-Ibcr and qepA) or
aminoglycosides (e.g. arm and rtm). Moreover, as some carb-
apenemase determinants are associated with integrons, other
resistance cassettes, such as those involving aminoglycoside
or trimethoprim, and sulphonamide (sul) resistance genes,
should also be considered. In addition, it is interesting to
monitor the simultaneous presence of other b-lactamase
genes such as those encoding ESBLs or AmpC-type enzymes.
This association is no longer a rarity [1,14,72,73].
Surveillance of carriers
Colonization with CP Enterobacteriaceae, particularly with CP
K. pneumoniae, has been associated with several healthcare-
associated factors, and higher mortality rates have been
observed among patients infected with CP isolates than
among those infected with non-CP isolates [74–76]. More-
over, patients with asymptomatic colonization are at risk of
invasive infection [77]. In outbreaks or in settings where CP
microorganisms are endemic, screening for asymptomatic
carriers must be considered, as this procedure has been
shown to be helpful in reducing the incidence of CP organ-
isms [78]. The appropriate source/biological material for this
procedure has not been speciﬁcally determined for CP En-
terobacteriaceae but depends on the prevailing organism.
Moreover, general guidelines for multidrug-resistant organ-
isms should be followed (CDC, Healthcare Infection Control
Practices Advisory Committee. Management of multidrug-
resistant organisms in healthcare settings, 2006. Atlanta, GA:
US Department of Health and Human Services, CDC,
Healthcare Infection Control Practices Advisory Committee,
2007. Available at http://www.cdc.gov/ncidod/dhqp/pdf/ar/
mdroguideline2006.pdf.). Suitable materials for the screening
of CP strains are: (i) rectal swabs or stools for isolation of
Enterobacteriaceae; (ii) respiratory specimens and/or stools
for pseudomonads; and (iii) nasal swabs, axilla swabs and/or
stools for A. baumannii [79].
Agar or broth media supplemented with a low-concentra-
tion carbapenem may be used. MacConkey agar containing
imipenem at a concentration of 1 mg/L, or a 5-mL aliquot of
tryptic soy broth containing a 10-lg disk of imipenem
(resulting in a ﬁnal concentration of imipenem of 2 mg/L),
are suitable [80]. In addition, the use of MacConkey agar
onto which a 10-lg disk of imipenem or ertapenem is placed
has also been reported [77,78,80].
Regarding the KPC-producing isolates, screening with the
new chromogenic medium (CHROMagar KPC; CHROMagar
Company, Paris, France), which is supplemented with agents
that inhibit the growth of carbapenem-susceptible organisms,
has been proposed [81]. The method has been validated only
in a small number of samples containing KPC-producing
K. pneumoniae isolates. After the initial screening, the carba-
penem-resistant isolates are investigated by phenotypic and
molecular assays. This CHROMagar KPC medium is not
selective for screening KPC-producing isolates, as it may also
be used in screening for producers of other types of carba-
penemases. Conversely, it should be noted that selective
plates for ESBL-producing organisms (e.g. MacConkey agar
containing ceftazidime or cefotaxime, or selective chromo-
genic agars) can be useful, although such a method is not yet
validated. Bacteria growing on these plates must be checked
for carbapenemases.
Molecular techniques such as PCR or real-time PCR have
the potential to be used directly on biological material
without prior cultivation. The approach could be useful,
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especially in outbreak settings or in areas with a high preva-
lence of CP microorganisms, where the timely cohorting of
patients is extremely important for preventing the further
spread of CP organisms.
In outbreak settings, after the initial screening, the putative
carbapenemase producers should be forwarded to a refer-
ence laboratory for further conﬁrmation of carbapenemase
activity by spectrophotometric assays and for identiﬁcation
of different carbapenemases.
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